Comparison · NCT02251041-285beca2
Combined Drug Approach vs Controles: Post-Reperfusion Syndrome
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Combined Drug Approach vs Controles: Post-Reperfusion Syndrome. Trial comparisons, record NCT02251041-285beca2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02251041-285beca2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.241 | 0.122 | 0.421 | wilson | |
| Risk in group 2 | 0.207 | 0.0985 | 0.384 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0345 | -0.179 | 0.244 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.17 | 0.446 | 3.05 | log | |
| Odds ratio, group 1 over group 2 | 1.22 | 0.354 | 4.2 | log | |
| Number needed to treat, for one more participant with the outcome on Combined Drug Approach than on Controles | 29 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Combined Drug Approach | the group receives a combination of drugs~Antithrombin-III~Infliximab~Apotransferrin~Human recombinant erythropoietin~C1-Inhibitor~Glutathione~Alfa-tocopherol~Melatonin~Epoprostenol | 7 | 29 | OG000 |
| Group 2 | Controles | the group do not receive a combination of drugs, but a placebo (sodium chloride solution)~Sodium chloride solution | 6 | 29 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Post-Reperfusion Syndrome
- Description
- Post-reperfusion syndrome defined as a 30% decrease of mean systemic blood pressure for more than 1 minute during the first 5 minutes following graft reperfusion
- Time frame
- first 5 minutes following graft reperfusion
- Population
Source ClinicalTrials.gov
Trial
- Title
- Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)
- NCT number
- NCT02251041
- Phases
- PHASE2
- Conditions
- Reperfusion Injury
- Interventions
- Antithrombin-III, Infliximab, Apotransferrin, Human recombinant erythropoietin, C1-Inhibitor, Glutathione, Alfa-tocopherol, Melatonin, Epoprostenol, Sodium chloride solution
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Results first posted
- 2024-08-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02251041?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02251041-285beca2